You are here

Rhomed, Inc.

Company Information
Address
C/O PALATIN TECHNOLOGIES, INC.
Princeton, NJ 08540
United States



Information

UEI: N/A

# of Employees: N/A


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. STABLE TUFTSIN METALLOPEPTIDE IMMUNOSTIMULATORY AGENT

    Amount: $100,000.00

    N/A

    SBIRPhase I1996Department of Health and Human Services
  2. RATIONALLY DESIGNED 99MTC RGD LIGANDS FOR CLOT IMAGING

    Amount: $94,970.00

    N/A

    SBIRPhase I1996Department of Health and Human Services
  3. TC-99M SOMATOSTATIN ANALOGS FOR IMAGING TUMORS

    Amount: $100,000.00

    N/A

    SBIRPhase I1996Department of Health and Human Services
  4. NOVEL 99MTC-TUFTSIN FOR IMAGING INFLAMMATION FOCI

    Amount: $93,948.00

    N/A

    SBIRPhase I1996Department of Health and Human Services
  5. DIRECT RADIOMETAL LABELING FOR IMAGING AND THERAPY

    Amount: $50,000.00

    ANTIBODIES OR ANTIBODY FRAGMENTS, REDUCED AND LYOPHILIZED FOR USE IN PREPARING INSTANT, ONE-STEP TC-99M RADIOPHARMACEUTICALS, CAN ALSO BE LABELED WITH CU-67. THE CU-67, AS CU(II) IN A PH 5.6 BUFFER, I ...

    SBIRPhase I1992Department of Health and Human Services
  6. OPPORTUNISTIC INFECTION IMAGING IN AIDS

    Amount: $46,211.00

    OPPORTUNISTIC INFECTIONS ARE A MAJOR CAUSE OF MORBIDITY AND MORTALITY IN AIDS PATIENTS. ALTHOUGH IT IS GENERALLY BELIEVED THAT THE EARLY DIAGNOSIS AND TREATMENT OF AN OPPORTUNISTIC INFECTION IS CRITIC ...

    SBIRPhase I1992Department of Health and Human Services
  7. TC-99M-LABELED CHEMOTACTIC PEPTIDES FOR ABSCESS IMAGING

    Amount: $50,000.00

    FORMULATED CHEMOTACTIC PEPTIDES, WITH ENDOGENOUS TC-99M BINDING SITES, WILL BE DEVELOPED FOR USE IN LOCALIZING ABSCESSES, INFLAMMATIONS, AND INFECTIONS. THE PEPTIDES ARE DESIGNED TO HAVE THE BIOLOGICA ...

    SBIRPhase I1992Department of Health and Human Services
  8. TC-99M-LABELED LAMININ FRAGMENTS FOR CANCER IMAGING

    Amount: $50,000.00

    THE OBJECTIVE IS DEVELOPMENT OF A RADIOPHARMACEUTICAL, USING A SYNTHETIC LAMININ NONAPEPTIDE RADIOLABELED WITH TC-9M, FOR DETECTION AND LOCALIZATION OF METASTATIC TUMOR CELLS OF EPITHELIAL ORIGIN. THE ...

    SBIRPhase I1992Department of Health and Human Services
  9. IMPROVED TECHNETIUM-99M LABELING FOR CANCER IMAGING

    Amount: $500,000.00

    A NEW METHOD OF DIRECT LABELING OF ANTIBODIES WITH TECHNETIUM-99M (TC-99M) WILL BE DEVELOPED AND EVALUATED. INTHIS METHOD, CALLED THE REGULATED REDUCTION METHOD, ONE CHEMICAL MEANS IS USED TO BREAK TH ...

    SBIRPhase II1991Department of Health and Human Services
  10. 99M TC-PHA-L4 LABELED LYMPHOCYTES

    Amount: $50,000.00

    THE OBJECTIVE OF THE STUDY IS TO DEVELOP A PAN-T-LYMPHOCYTE 99MTC-RADIOTRACER WHICH CAN BE USED TO STUDY TRAFFICKING OF STIMULATED LYMPHOCYTES AND AS A DIAGNOSTIC RADIOPHARMACEUTICAL FOR CHRONIC INFEC ...

    SBIRPhase I1991Department of Health and Human Services
US Flag An Official Website of the United States Government